Kidney thrombotic microangiopathy with concurrent monoclonal gammopathy
Nephrology Dialysis Transplantation · 2025
DOI: 10.1093/ndt/gfae191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Meng Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Peking University First Hospital. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Paraproteinemias, Kidney Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Capital's Funds for Health Improvement and Research, Beijing Natural Science Foundation, Peking University First Hospital.
Abstract (Originalsprache)
Background
The concurrence of monoclonal gammopathy and thrombotic microangiopathy (TMA) has been suggested in a few studies. However, the complement activation was not fully studied in previous cases. In this study, we aimed to determine the complement activation in these group of patients and the association with clinical, laboratory and pathological features.
Methods
Between 2007 and 2020, 20 patients with biopsy-proven renal TMA and monoclonal gammopathy in Peking University First Hospital were included in the study. Complement activation was tested by enzyme-linked immunosorbent assay. Associations with clinical features, pathological data and laboratory findings were further investigated.
Results
Among renal TMA patients beyond 50 years of age, the prevalence of monoclonal gammopathy was 16.51% (18/109) which is almost 4-fold greater than the expected rate in population (4.2%). Eleven patients had acute kidney injury, and two patients required dialysis. Hematological diagnosis was consistent with monoclonal gammopathy of undetermined significance (MGUS) (n = 10), unconfirmed MGUS (n = 3), POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndromes (n = 4), Castleman's disease (n = 2) and chronic lymphocytic leukemia (n = 1). A majority of patients (84.2%) showed the activation of complement classical pathway. Fifteen percent (3/20) of patients received conservative therapy, 5% (1/20) received steroid only, 30% (6/20) with immunosuppression and 50% (10/20) received clone-targeted chemotherapy. During a median 56 months of follow-up, end-stage renal disease developed in two patients, and five patients died mainly because of hematological progression.
Conclusion
This study found the dysregulation of complement activation, especially the classical pathway, involved in the pathogenesis of biopsy-proven renal TMA and monoclonal gammopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Division, Department of Medicine, Peking University First Hospital.
- Institute of Nephrology, Peking University, Beijing, China.
- Key laboratory of Renal Disease, Ministry of Health of China.
- Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China.
- Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Nephrology, Yantai Yuhuangding Hospital, Yantai, China.
Förderung
- Capital's Funds for Health Improvement and Research
- Beijing Natural Science Foundation
- Peking University First Hospital
- Fundamental Research Funds for the Central Universities
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Tan, M., Jia, C., Liu, X., Wu, D., Yu, X., Zhao, M., & Tan, Y. (2025). Kidney thrombotic microangiopathy with concurrent monoclonal gammopathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae191
Vancouver
Tan M, Jia C, Liu X, Wu D, Yu X, Zhao M, et al. Kidney thrombotic microangiopathy with concurrent monoclonal gammopathy. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfae191
BibTeX
@article{Tan2025,
author = {Tan, Meng and Jia, Changhao and Liu, Xiaotian and Wu, Daoxu and Yu, Xiaojuan and Zhao, Minghui and Tan, Ying},
title = {Kidney thrombotic microangiopathy with concurrent monoclonal gammopathy},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
doi = {10.1093/ndt/gfae191}
}
EUVIMED